Novartis charged $422.5 million to settle off-label charges
This article was originally published in Scrip
Executive Summary
Not the first and unlikely to be the last, Novartis has agreed to pay $422.5 million to settle claims of off-label marketing of its seizure therapy Trileptal (oxcarbazepine) and five other products.